OptimizeRx Corp (OPRX) reporting person Doug Besch had 3,325 restricted stock units vest on 10/03/2025, which converted one‑for‑one into 3,325 shares of common stock at a zero exercise price. Following the vesting, the reporting person beneficially owned 70,555 shares. The issuer withheld 983 shares to satisfy tax withholding obligations at a price of $18.75, treated as a disposition for Section 16 purposes, leaving 69,572 shares shown as directly owned after that disposition. The RSUs vest in three equal annual installments beginning 10/03/2023. The filing was signed by power of attorney on 10/07/2025.
OptimizeRx Corp (OPRX) reported that Andrew J. D'Silva, the company's Chief Business Officer and a director, received equity awards on 08/21/2025. He was granted 10,417 restricted stock units (RSUs) that represent a contingent right to receive common stock and 23,437 stock options with an exercise price of $16.14. After these grants, Mr. D'Silva beneficially owns 47,514 shares23,437 option-related shares exercisable into common stock.
The RSUs and the stock option award both vest in three equal annual installments beginning on 08/21/2026, the first anniversary of the grant, with the option expiring on 08/21/2030. The filing is a Form 4 reporting the grant; it includes a customary remark clarifying that the filing is not an admission of beneficial ownership for Section 16 purposes.
OptimizeRx Corp (OPRX) officer Andrew J. D'Silva reported beneficial ownership of 37,097 shares of common stock, including 24,890 shares represented by unvested restricted stock units (RSUs). The filing lists five stock option grants covering 78,626 underlying shares with exercise prices of $7.20, $67.31, $15.04, $12.73, and $4.95 and exercisable on dates through 10/01/2029. Several RSU and option tranches vest between 10/01/2025 and 12/19/2026.
OptimizeRx director Patrick D. Spangler reported selling 11,120 shares of OptimizeRx Corp (OPRX) on 08/28/2025 at a weighted average price of $17.49 per share, with individual sale prices ranging from $17.47 to $18.43. After the reported disposition the filing shows the reporting person beneficially owned 44,215 shares, held directly. The Form 4 indicates the sale was executed in multiple transactions and the filer offers to provide detailed per-price allocation on request. The statement is limited to this single non-derivative sale and includes a standard reservation that the filer does not concede beneficial ownership for all purposes.
OptimizeRx Corporation (OPRX) notice reports a proposed sale under Rule 144 of 11,120 shares of common stock, with an aggregate market value of $198,000. The filing identifies the broker as Merrill, 80 South 8th Street, Minneapolis, MN, and lists the approximate date of sale as 08/28/2025 on Nasdaq. The shares were acquired through a series of restricted stock awards from OptimizeRx between March 31, 2019 and March 31, 2020, with vesting/payment dates shown in 2019–2020. The filer states there were no securities sold in the past three months and certifies no undisclosed material adverse information is known.
OptimizeRx Corp (OPRX) reporting person Stephen L. Silvestro, identified as Chief Executive Officer and Director, reported acquisitions on 08/21/2025. He was granted 15,625 restricted stock units (RSUs) that carry a contingent right to receive common shares and will vest in three equal annual installments beginning August 21, 2026. He also received a stock option for 35,156 shares with an exercise price of $16.14; the option vests in three equal annual installments beginning August 21, 2026 and is exercisable from August 21, 2026 through August 21, 2030. Following these reported transactions, the filing shows 183,887 shares of common stock and 35,156 derivative securities beneficially owned. The Form 4 was signed by power of attorney on August 25, 2025.
OptimizeRx officer Marion K. Odence-Ford was granted 15,625 restricted stock units and a stock option for 35,156 shares on 08/21/2025. The RSUs vest in three equal annual installments beginning 08/21/2026. The option has an exercise price of $16.14, vests in three equal annual installments beginning 08/21/2026, is exercisable 08/21/2026 and expires 08/21/2030. Following the awards, Odence-Ford beneficially owns 85,901 shares of common stock and holds options/rights covering 35,156 additional shares.
OptimizeRx Corp. CFO/COO Edward Stelmakh reported equity awards on Form 4 showing a grant of 15,625 restricted stock units and a stock option for 35,156 shares. The restricted stock units vest in three equal annual installments beginning August 21, 2026. The option has an exercise price of $16.14, vests in three equal annual installments beginning August 21, 2026, is exercisable starting August 21, 2026 and expires August 21, 2030. After these transactions, Mr. Stelmakh beneficially owns 110,764 shares of common stock and 35,156 underlying shares from the option.
OptimizeRx Chief Commercial Officer Theresa Greco reported awards on Form 4 consisting of 15,625 restricted stock units and a stock option for 35,156 shares granted on 08/21/2025. The restricted stock units are a contingent right to receive common stock and will vest in three equal annual installments beginning on August 21, 2026. The stock option has an exercise price of $16.14, vests in three equal annual installments beginning August 21, 2026, is exercisable from 08/21/2026, and expires on 08/21/2030. Following the grant, Ms. Greco beneficially owns 75,981 shares of common stock and 35,156 option shares exercisable.
OptimizeRx insider grant summary: Chief Product & Tech Officer Doug Besch received equity awards on 08/21/2025. The Form 4 reports a grant of 15,625 restricted stock units (RSUs) that vest in three equal annual installments beginning 08/21/2026. The filing also reports a stock option for 35,156 shares with an exercise price of $16.14, vesting in three equal annual installments beginning 08/21/2026 and expiring 08/21/2030. Following the reported transactions, the filing shows 67,230 shares of common stock beneficially owned and 35,156 underlying shares from the option.